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Abstract
Background: Gastrointestinal (GI) dysfunction is frequent in the critically ill but can be overlooked as a result of the
lack of standardization of the diagnostic and therapeutic approaches. We aimed to develop a research agenda for
GI dysfunction for future research. We systematically reviewed the current knowledge on a broad range of
subtopics from a specific viewpoint of GI dysfunction, highlighting the remaining areas of uncertainty and
suggesting future studies.
Methods: This systematic scoping review and research agenda was conducted following successive steps: (1)
identify clinically important subtopics within the field of GI function which warrant further research; (2)
systematically review the literature for each subtopic using PubMed, CENTRAL and Cochrane Database of
Systematic Reviews; (3) summarize evidence for each subtopic; (4) identify areas of uncertainty; (5) formulate and
refine study proposals that address these subtopics; and (6) prioritize study proposals via sequential voting rounds.
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Results: Five major themes were identified: (1) monitoring, (2) associations between GI function and outcome, (3)
GI function and nutrition, (4) management of GI dysfunction and (5) pathophysiological mechanisms. Searches on
17 subtopics were performed and evidence summarized. Several areas of uncertainty were identified, six of them
needing consensus process. Study proposals ranked among the first ten included: prevention and management of
diarrhoea; management of upper and lower feeding intolerance, including indications for post-pyloric feeding and
opioid antagonists; acute gastrointestinal injury grading as a bedside tool; the role of intra-abdominal hypertension
in the development and monitoring of GI dysfunction and in the development of non-occlusive mesenteric
ischaemia; and the effect of proton pump inhibitors on the microbiome in critical illness.
Conclusions: Current evidence on GI dysfunction is scarce, partially due to the lack of precise definitions. The use
of core sets of monitoring and outcomes are required to improve the consistency of future studies. We propose
several areas for consensus process and outline future study projects.
Keywords: Gastrointestinal function, Gastrointestinal dysfunction, Gastrointestinal failure, Monitoring, Critically ill,
Intensive care
Background
Gastrointestinal (GI) dysfunction is frequently seen in crit-
ically ill patients and is associated with worse clinical out-
comes [1]. GI dysfunction refers broadly to functional
impairment of the GI tract that may include disturbances
in motility and/or absorption, breaches in mucosal integ-
rity, changes in the microbiome, increased intra-
abdominal pressure, impaired mesenteric perfusion infec-
tions of the GI tract and other clinical consequences dis-
played in Fig. 1. These functional impairments may
contribute to patient morbidity, may aggravate multi-
organ failure and may further deteriorate to life-
threatening emergencies (bowel ischaemia, Ogilvie’s syn-
drome, GI tract perforation, GI bleeding, abdominal com-
partment syndrome). The underlying pathophysiology of
GI dysfunction in critically ill patients comprises several
components whose respective influence and relevance are
poorly understood. Available monitoring techniques are
limited [2], and management options are scarce [3].
We aimed to develop a research agenda for GI dys-
function giving a concise overview of different aspects
on GI dysfunction for clinicians and offer a starting
point for future research. We did not aim to issue rec-
ommendations for clinical practice but rather give a
basis for future research that is needed for evidence-
based recommendations.
As a first step, we predefined our research themes and
subtopics and performed a systematic scoping review to
summarize current knowledge in the field (what we
know). We address a broad range of subtopics from a
specific viewpoint of GI dysfunction selected by a group
of experienced ICU physicians specifically dedicated to
this topic, also explaining the pathophysiological aspects
that need to be further explored before several clinical
questions can be answered and monitoring technologies
developed. Five major themes related to GI dysfunction
were selected a priori: (1) monitoring, (2) associations
between GI dysfunction and outcome, (3) GI function
and nutrition, (4) management of GI dysfunction and (5)
pathophysiological mechanisms. With including experi-
mental research, addressing pathophysiological hypoth-
eses and monitoring, we aimed to provide a broader
view and background for future studies rather than a
strict assessment of clinical studies in adult critically ill
patients.
As next steps, we highlight the key remaining areas of
uncertainty (what we do not know) and suggest recom-
mendations for studies/trials (what we need to know).
We focus on GI dysfunction as a part of multiple organ
dysfunction but do not specifically address interventional
management of GI emergencies (e.g. bowel ischaemia or
perforation, GI bleeding).
Methods
The project was initiated by the Section of Metabolism,
Endocrinology and Nutrition (MEN) of the European
Society of Intensive Care Medicine (ESICM) and en-
dorsed by ESICM. In October 2017, the Working Group
(WG) on GI Function within the MEN Section formu-
lated the following steps of the process: (1) identify clin-
ically important subtopics within the a priori identified 5
major themes of GI function which warrant further re-
search, (2) systematically review the literature for each
subtopic, (3) summarize evidence for each subtopic, (4)
identify areas of uncertainty, (5) formulate and refine
study proposals that address these subtopics and (6)
prioritize study proposals via sequential voting rounds.
The group communicated via e-mail and met four times
remotely and twice a year physically during the WG
meeting at congresses. The process of voting was dis-
cussed and agreed on during the WG meeting in Octo-
ber 2018 and conducted in winter 2019. All MEN
Section members were asked for their interest to partici-
pate in voting, and all interested members were invited
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to participate in voting. Voting was conducted in two
Delphi rounds, where voting 1 was a shortlisting of all
the proposals, and voting 2 was a quality assessment of
the 20 highest ranked proposals. Methods in detail and
conflicts of interest are presented in Additional file 1.
Results
Summary of evidence is presented in Table 1 and in Add-
itional file 2, all developed study proposals in Add-
itional file 3, summary on monitoring and motility in
Additional file 4, PRISMA (Preferred Reporting Items for
Systematic reviews and Meta-Analyses) checklist in Add-
itional file 5 and PRISMA flow diagrams for each system-
atic review in Additional file 6.
Current knowledge in the field (what we know)
Monitoring of GI function
Current techniques for monitoring GI dysfunction in
critically ill patients are limited [2]. Clinical assessment,
often combined with measurement of gastric residual
volumes (GRV), is widely used but provides an imprecise
assessment of global GI function. Possible techniques to
monitor GI function are summarized in Additional file 4,
Table S5.
Clinical assessment
GI symptoms occur frequently in the critically ill [1]. No
single symptom correlates with mortality, whereas an in-
creasing number of concomitant GI symptoms are asso-
ciated with increasing mortality [1]. There is no agreed
and validated scoring system for the assessment of GI
dysfunction [3, 4]. The presence of GI bleeding that has
been used as a symptom identifying GI dysfunction in
multiple organ failure scores [5, 6] is not necessarily re-
lated to gut dysfunction, as there are numerous specific
causes and therapeutic modalities [7]. Likewise, delayed
gastric emptying leading to increased GRV can occur in
the absence of intestinal dysfunction. Moreover, using a
feeding strategy based on GRV may lack relevance, as it
did not decrease the risk of ventilator-associated
Fig. 1 Pathophysiological mechanisms and multi-faceted clinical presentation of GI dysfunction. Critical illness is associated with gastrointestinal
(GI)-related (patho)biochemical/physiological mechanisms which can be both cause and consequence of the disease, respectively. These
mechanisms again have clinical effects/sequelae that further lead to life-threatening conditions depending on the grade of severity and
concordantly affect the clinical outcome. The relationship between these mechanisms (as marked by the arrows) is not linear; they rather occur in
parallel and may aggravate each other
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Table 1 Summary of evidence in predefined subtopics related to gastrointestinal dysfunction (what we know). More details on the
literature behind statements in this table are presented in Supplement 2 Table S3
Subtopic Study questions Main observations
Monitoring of GI function
i. Clinical assessment Can GI symptoms* and/or clinical signs
be used to monitor GI function in critically
ill patients?
- There is no gold standard for monitoring
of GI function in critically ill.
- GI symptoms and clinical signs may be used,
and the number of GI symptoms is associated
with increased mortality.
- GI symptoms/signs have not been clearly
correlated with other objective methods
quantifying GI function.
ii. Imaging Can imaging be used to monitor GI
function in critically ill?
- No validated imaging method for bedside
monitoring.
- GI ultrasound is promising but requires further
study.
iii. Laboratory (including biomarkers) Can biomarkers be used to monitor GI
function in critically ill?
- No biomarker is validated for clinical use.
- Host-, disease- and analytics-related factors may
influence potential biomarkers of interest.
- Most of the studies assess biomarkers of mesenteric
ischaemia or organ dysfunction.
iv. Absorption of nutrients Can absorption of nutrients be measured
to monitor GI function?
- No method to measure absorption is available for
routine clinical use.
v. Barrier function Can barrier function be measured to
monitor GI function?
- No valid method to measure barrier function is
available for routine clinical use.
vi. Others (including intra-abdominal
pressure (IAP))
Which other monitoring methods can
be used to monitor GI function?
- IAP can be easily measured and gives a numeric
value reflecting abdominal compartment.
- Association with GI function is unclear.
- Grossly elevated and increasing IAP may
necessitate discontinuation or reduction of EN.
Management of GI dysfunction
vii. Prokinetics -Do prokinetics improve upper GI motility
in critically ill?
- Do prokinetics improve lower GI motility
in critically ill?
- Does combined treatment of upper and lower
GI intolerance improve GI motility in critically ill?
- Do prokinetics improve other clinically relevant
outcomes?
Gastric emptying:
- Erythromycin accelerates gastric emptying and
may
be superior to metoclopramide.
- The effect of combination metoclopramide and
erythromycin is sustained for longer than either
drug alone.
Lower GI dysmotility: insufficient data.
Combined treatment of upper and lower GI motility:
insufficient data
Uncertainty with regards to:
- Recommended dose of erythromycin (3 × 100 mg
vs 200–250mg) and therapy duration.
- Repeated treatment with gastroprokinetics.
- Definition of lower GI intolerance/dysmotility.
- Effect on morbidity and mortality.
viii. Laxatives Do laxatives improve GI function, morbidity
and mortality in critically ill patients?
- Possible benefit of prophylactic therapy
(polyethylene glycol, lactulose) regarding time
to defaecation, but not regarding complications.
- Polyethylene glycol probably better than lactulose,
suggested to reduce the incidence of Ogilvie’s
syndrome.
ix. Post-pyloric feeding Does post-pyloric feeding improve GI
function, morbidity and mortality in
critically ill patients receiving EN?
- Post-pyloric feeding may reduce the number
of patients who develop ventilator-associated
pneumonia.
- Mostly small studies in patients without feeding
intolerance.
- Heterogeneity of intervention, i.e. different location
of tubes (duodenal and jejunal) pooled.
x. Others Which other management improves GI
function, morbidity and mortality in
critically ill?
- None confirmed in critically ill in general.
- In postoperative patients, ERAS protocol and
epidural analgesia may improve GI motility.
- Beneficial effect of any specific (e.g. restrictive) fluid
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pneumonia in ventilated medical patients with full en-
teral nutrition (EN) [8]. Several methods to assess gastric
emptying (e.g. scintigraphy, paracetamol absorption test)
are mostly used for the purpose of research (Add-
itional file 4, Table S5).
Diarrhoea has been suggested as a marker of malab-
sorption [9] and could also be considered as a sign of
feeding intolerance, but existing evidence is scarce [10].
Clinical symptoms, including diarrhoea, can signal a
non-occlusive mesenteric ischaemia (NOMI) that may
occur related to early full EN during acute circulatory
failure [11].
Imaging
Recent studies demonstrated the potential for ultrasound
(US) to provide a measure of (1) gastric emptying, (2)
bowel peristalsis, (3) bowel diameter, (4) bowel wall
thickness and (5) tissue perfusion (US Doppler). The
diameter of the gastric antrum measured with US corre-
lates with both GRV and calculations based on CT
Table 1 Summary of evidence in predefined subtopics related to gastrointestinal dysfunction (what we know). More details on the
literature behind statements in this table are presented in Supplement 2 Table S3 (Continued)
Subtopic Study questions Main observations
management strategy on GI function has not
been proven.
xi. GI function and nutrition Does EN improve GI function, morbidity
and mortality in critically ill?
- EN may preserve GI immunity and attenuate
proinflammatory changes and bacterial
overgrowth.
- The quantity of nutrients absorbed with EN
during critical illness is uncertain.
- EN has not been shown to improve patient-
centred outcomes.
Pathophysiological mechanisms in GI dysfunction relevant to the outcome
xii. The role of the gut in multiple
organ failure
What is the evidence on the role of the
GI dysfunction in the development and
course of MOF?
Indirect evidence supports a role of GI
dysfunction in the development/perpetuation
of MODS suggested by associations between the
severity of GI dysfunction and organ failures.
xiii. Microbiome What is the evidence on the role of
the microbiome in GI dysfunction?
Observational data have shown an association
between critical illness (severity) and change of
the intestinal microbiome as compared to the
healthy state (‘dysbiosis’). Change in microbiome
is suggested to be associated with GI dysfunction
and clinical outcome but has yet to be confirmed
by adequately powered studies.
xiv. Bacterial translocation/mucosal
integrity
What is the evidence on bacterial
translocation/mucosal integrity in GI
dysfunction?
Reported associations between the presence
of enteric bacteria or bacterial products in
the circulation, presumably related to gut
dysfunction and poor outcome. Gut microbiota
or related products (e.g. DAMPs in lymphatic
ducts, endotoxins in portal blood) may trigger
distant organ damage in GI dysfunction.
xv. GI hormones What is the evidence that endogenous
GI hormones are important in modulating
GI dysfunction?
A decrease in the plasma concentration of
orexigenic hormones (e.g. ghrelin) and an
increase of anorexigenic hormones (e.g. PYY)
during the early phase have been observed.
No direct correlation with the GI function has
been reported.
xvi. Bile acid signalling What is the evidence on bile acid
signalling in GI dysfunction?
Bile acid signalling as a mechanism of GI
dysfunction has not been studied in adult
critically ill patients, but increased levels of
bile acids in circulation are associated with
adverse outcome.
xvii. Others What is the evidence on other mechanisms
in GI dysfunction?
Bowel oedema and bowel distension have
not been studied in critically ill patients.
Bowel oedema impaired motility in
experimental study.
DAMP damage-associated molecular pattern, EN enteral nutrition, ERAS enhanced recovery after surgery, IAH intra-abdominal hypertension, IAP intra-abdominal
pressure, FI feeding intolerance, GI gastrointestinal, MODS multiple organ dysfunction syndrome, RCT randomized controlled trial
*GI symptoms include vomiting/regurgitation, abdominal distension, GI bleeding, diarrhoea and lower GI paralysis [3]. Expanded (if performed/possible to assess)
nausea, abdominal pain, absence of bowel sounds, large GRV (> 500 mL/6 h), bowel dilatation (radiological) and bowel wall thickening/bowel
oedema (radiological)
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images [12]. US may also facilitate the placement of
feeding tubes and therefore is an imaging technique that
could potentially be incorporated into regular abdominal
assessment (Additional file 4, Table S5) [13].
Biomarkers
Besides blood L-lactate, several novel biomarkers have
been proposed [14] (Additional file 4, Table S6). Citrul-
line levels may represent enterocyte function [15], and
citrulline concentrations < 10 μmol/L are associated with
increased mortality [16]. Specific aspects and pitfalls for
laboratory measurements are summarized (Add-
itional file 4). Despite encouraging preliminary results,
several factors may limit the translation of novel bio-
markers to clinical practice including (1) the timing of
sampling, (2) the extent of surgical damage, (3) the coex-
istence of other organ dysfunction (e.g. renal), (4) previ-
ous gut surgery and length of intact bowel and (5)
precision of laboratory technique, threshold values
chosen and rapidity of the result [17].
Absorption of nutrients
Small cohort studies have demonstrated that absorption
of macronutrients is markedly attenuated in the critically
ill when compared to health [18–20]. Nutrient analogues
or nutrient labelled with an isotope (e.g. 3-O-methyl-glu-
cose or 13C-glucose) can be administered with enteral
nutrition and subsequently sampled from the blood and/
or other body fluids to quantify nutrient absorption [18–
20]. The results of absorption studies may substantially
vary depending on whether markers are administered
intragastrically or intraduodenally, especially if gastric
emptying is delayed [21]. The duodenal approach will
better reflect the actual absorption, whereas the former
might be more representative of the actual nutrient
(bio)-availability during routine clinical practice.
Utilization of enterally administrated nutrients can be
quantified using whole-body balance studies (Add-
itional file 4). However, the precision of this technique
requires accurate measurement of intake and output, in-
cluding output from urine, faeces and drains. Faecal en-
ergy loss can be measured as a marker of malabsorption
using bomb calorimetry [9], but this method is not
widely available and requires the passage of stool, which
is infrequent in many critically ill patients [10].
Barrier function
GI barrier dysfunction may be caused by (1) loss of en-
terocyte integrity, (2) increased transcellular/paracellular
permeability, (3) loss of mucus layer integrity and (4)
impaired mucosal immunity.
The GI barrier can be visualized using electron mi-
croscopy [22], but this invasive approach requires tissue
biopsy and only quantifies structure at the place and
time tissue is obtained. GI barrier function is the net re-
sult of a myriad of interactions between the luminal con-
tent, the epithelium and the mucosal immune system
[23]. Because any or all of these components may be
dysregulated in critical illness, no single biomarker
(Additional file 4 Table S6) is likely to capture all of
these processes to provide a robust summary score.
Double/triple sugar absorption tests are used to deter-
mine paracellular permeability in ambulant populations.
However, these tests may be affected by GI dysmotility,
renal and/or liver impairment, and administration of an-
tibiotics [24], possibly limiting their usefulness in the
critically ill.
Quantification of specific enteral bacteria in the blood
is possible. However, confirming translocation from the
gut lumen as a direct result of gut barrier dysfunction is
challenging due to low rates and contamination. In HIV
patients, reverse transcription polymerase chain reaction
(RT-PCR) of bacterial 16S rDNA has been reported to
correlate with lipopolysaccharide blood concentration
[25]. This genetic information, however, does not refer
to gut-specific bacteria such as Enterococcus or Bacter-
oides species. The widely used quantification of endo-
toxin, corresponding antibodies or binding proteins is
neither gut- nor species-specific [26].
Other monitoring options
Intra-abdominal pressure (IAP) is readily measurable at
the bedside, and increased IAP may be both cause and
consequence of GI dysfunction. The definition of intra-
abdominal hypertension (IAH) and measurement of IAP
is described elsewhere [27]. In a study in mechanically
ventilated patients, the presence of IAH in the absence
of GI symptoms was not associated with mortality [28].
GI dysfunction: reporting and outcome
GI dysfunction has been shown to be associated with ad-
verse outcome, even though reported outcomes and
their definitions are very variable [4]. The importance of
agreement on a minimum collection of essential out-
comes within a given field (core outcomes set (COS))
has been recently highlighted [29].
Management of GI dysfunction
Current management of GI dysfunction mainly relies on
treating the underlying causes. In addition, specific
therapeutic interventions may be considered, but avail-
able options have substantial limitations.
GI motility drugs
Current options for treating delayed gastric emptying in-
clude drugs such as metoclopramide, erythromycin and
domperidone [30] (Additional file 4, Table S7). Domper-
idone is only available for oral administration, limiting
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its use in ICU patients. The combination of metoclopra-
mide and erythromycin may have synergistic effects and
be superior to either drug alone [31]; however, tachy-
phylaxis and arrhythmias are the limitations.
A recent meta-analysis reported that prokinetic drugs
modestly reduce feeding intolerance (absolute risk reduc-
tion 17.3% (95% CI 5–26.8%)) and facilitate the placement
of post-pyloric feeding tubes, but had no effect on the de-
velopment of pneumonia, vomiting and diarrhoea; mortal-
ity; or length of hospital stay [32]. An even more recent
meta-analysis provided similar results, but erythromycin
was the only prokinetic drug to reduce feeding intolerance
[33]. Due to concerns about adverse effects of erythro-
mycin, there is a considerable interest in the use of non-
antibiotic motilin agonists. The pre-emptive administration
of such motilin receptor agonist had a negligible effect on
nutrition provision in a recent multicentre clinical trial [34].
Neostigmine is shown effective in colonic paralysis
[35] and accordingly used as a treatment for acute co-
lonic pseudo-obstruction (Ogilvie’s syndrome) [36]. To
prevent GI paralysis, administration of opioid receptor
antagonists, osmotic laxatives (e.g. polyethylene glycol)
and stool softeners has been proposed (Additional file 4,
Table S7), but demonstrated effect of ‘bowel protocols’
is limited [37].
Post-pyloric feeding
Although the gastric route is the preferred method of
providing EN, international guidelines include recom-
mendations for the post-pyloric route option in patients
at high risk of aspiration or with gastric feeding intoler-
ance [33, 38]. It is important to note that most of the
trials and available meta-analyses [38, 39] have not re-
stricted inclusion to patients with signs of GI
dysmotility.
Systemic management
Apart from systemic conditions such as sepsis and
shock, several interventions and specific conditions are
considered to contribute to GI dysfunction including (1)
intravenous fluid, and plasma glucose and electrolyte
concentrations; (2) the use of opioids for analgesia; and
(3) untreated intra-abdominal hypertension.
Intravenous fluid and plasma electrolytes There is
evidence demonstrating the association between exces-
sive fluid administration and GI dysfunction [40]. At the
same time, a recent large RCT in patients undergoing
major abdominal surgery reported no signal of fewer ep-
isodes of GI dysfunction but a greater number of renal
complications with a restrictive approach to periopera-
tive fluid administration [41]. There is currently insuffi-
cient evidence to support a restrictive fluid approach on
the rationale that it will reduce GI dysfunction.
Hyperglycaemia may slow gastric emptying, whereas
hypoglycaemia may accelerate it [42]. Interference of
serum electrolyte abnormalities with bowel motility has
been suggested [43], but there is insufficient data to tar-
get specific plasma electrolyte and glucose thresholds to
improve GI function.
Pain management and sedation Stimulation of either
opioid or alpha-2 adrenergic receptors may inhibit GI
motility [44, 45]. After colorectal surgery, faster recovery
of GI motility is achieved with the combination of early
postoperative feeding, multimodal analgesic regimens
and morphine restriction [46].
Intra-abdominal hypertension IAH can attenuate
splanchnic blood flow [47] and exacerbate bowel
oedema [48]. No intervention targeting IAH has been
shown to improve GI function or outcomes in the critic-
ally ill. Effect of IAH on the outcome depends on the se-
verity and dynamics of IAH [49].
GI function and nutrition
Whilst the dose of nutrition is beyond the scope of this
review, prolonged fasting (7 days when compared to 3
days) in the critically ill attenuated nutrient absorption
when EN was eventually administered [50]. Early EN
may preserve GI immunity, whereas prolonged starva-
tion may cause proinflammatory changes and bacterial
overgrowth [51].
On the other hand, a recent RCT demonstrated that
early full EN within 24 h in patients with shock was as-
sociated with increased risk for non-occlusive bowel is-
chaemia and colonic pseudo-obstruction [9]. Therefore,
the optimal strategy for feeding in shock remains uncer-
tain, but early full feeding may be harmful. Guidelines
recommend low-dose early EN (< 48 h of ICU admis-
sion) in critically ill patients who are not able to main-
tain oral intake [33, 52], whereas the extent of
absorption of enterally administered nutrients may vary
widely [20, 21].
Pathophysiological mechanisms in GI dysfunction
The role of the gut in multiple organ dysfunction syndrome
(MODS)
Animal models indicate that altered microbiome (see the
‘Microbiome’ section) during critical illness is associated
with loss of intestinal barrier [53]. This then allows the
translocation of bacterial products across the mucosa to
cause further inflammation and, finally, dysfunction of
remote organs (Fig. 1) [54]. For instance, acute lung in-
jury can occur following the release of gut-derived prod-
ucts into the lymphatic vessels and/or directly into the
lungs, as shown in a murine model and in humans [55].
In animal models, the ligation of the mesenteric lymph
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duct prevents the development of lung injury [56]. Like-
wise, intestinal dysbiosis may lead to hepatic impairment
[54]. In the clinical setting, inflammation induced by
translocation through disrupted gut epithelium will trig-
ger the administration of fluids and vasopressors. Fluid-
induced tissue oedema and mesenteric vasoconstriction
may amplify the pathophysiological processes in the gut
further and possibly lead to NOMI.
Microbiome
The microbiome refers to all of the microbial consortia
(both commensal and pathogenic bacteria, viruses and
fungi), their genes and gene products (proteins and me-
tabolites), their community structure (distribution, diver-
sity, and evenness) and the particulars of the environment
in which they reside. Essential functions of the gut micro-
biota include the synthesis, modulation and fermentation
of gastrointestinal metabolites. Moreover, the microbiome
has immunomodulatory properties [57].
Not only antibiotics but also other commonly used
drugs in the ICU can interfere with the gut microbiome
[58]. Endogeneous bacteria may play a beneficial role in
morbidity and mortality of acute illness [59]. However,
critical illness leads to disruption of the balance between
the intestinal epithelium (increased apoptosis, perme-
ability and mucus alterations all resulting in decreased
barrier function) and the microbiome (predominance of
pathological bacteria, increased virulence and antibiotic
resistance) [57, 60]. This transfer to a critical illness-
related ‘disease-promoting microbiome’ or ‘pathobiome’,
respectively, may lead to pro-inflammatory downstream
events in the intestinal epithelial cells, increased perme-
ability of tight junctions and mucus disintegration, all of
which are considered to be associated—both as a cause
and consequence—with gastrointestinal injury and
multi-organ dysfunction syndrome (MODS) [50, 60].
Emerging, but still preliminary, data in critically ill pa-
tients suggest the following: (1) the presence of specific
gastrointestinal microbial pathogens at ICU admission is
associated with an increased risk for death or all-cause
infection, and rectal carriage of common ICU pathogens
may predict specific infections [61]; (2) microbiome of
critically ill patients undergoes a significant and rapid
dysbiosis with loss of diversity, loss of site specificity and
a shift toward dominant pathogens as compared to
healthy controls [62]; (3) selective decontamination of
the digestive tract (SDD)-treated critically ill patients de-
viate strongly from the gut microbiota of healthy sub-
jects, whereas recolonization of the gut by antibiotic-
resistant bacteria may occur upon ICU discharge and
cessation of SDD [63]; and (4) lung microbiome is
enriched with gut bacteria in acute respiratory distress
syndrome [54].
Gastrointestinal mucosal integrity
As described (the ‘The role of the gut in multiple organ
dysfunction syndrome (MODS)’ section), in animal
models, the gut plays a pivotal role to precipitate MODS.
Peterson and Artis have suggested that the intestinal
epithelial cells with all the different phenotypes (i.e.
enterocytes, goblet cells, Paneth cells, enteroendocrine
cells, M cells and intestinal epithelial stem cells) should
be recognized as the central regulatory components of
barrier function and immune homeostasis [64]. Secre-
tion of epithelial-derived mucins, antimicrobial peptides
and IgA create the first line of defence, whilst the tight
epithelial lining builds up a physical border. Special cell
populations like M cells and dendritic cells act as sen-
sors for pathogens/antigens that activate the local im-
mune response if necessary. Functional or physical loss
of this epithelial integrity can lead to further harm [65].
Translocation of (patho)antigens across the epithelial
lining may result in the activation of intestinal macro-
phages and leucocyte recruitment (i.e. intestinal T lym-
phocytes CD4+ alpha4beta7+ CCR9+) to the intestinal
mucosa. The release of cytokines (i.e. tumour necrosis
factor, interleukin-1 beta and interleukin-10), reactive
oxygen species and nitric oxide may aggravate the intes-
tinal barrier failure and impair gastrointestinal motility
by disruption of the tight junctions and smooth muscle
contractile elements [66].
GI hormones
Molecules secreted from the GI tract may have local
effects to modulate motility, mucosal growth and im-
mune function and/or distal hormonal effects on
other systems, particularly metabolism [67, 68].
Plasma concentrations of enterohormones have there-
fore been evaluated as a technique to monitor GI
function, but none of them is currently clinically used
for this purpose (Table S6). However, the precise re-
lation between GI hormones and GI dysfunction is
insufficiently understood.
Bile acid signalling
Bile acids have been suggested as a mediator for organ
dysfunction [69]. Altered bile acid homeostasis in paedi-
atric patients with intestinal failure has been postulated
to contribute to liver dysfunction via increased hepatic
bile acid synthesis due to a failing feedback mechanism
[70]. Intrahepatic cholestasis of the critically ill is a
consequence of alterations of bile acid signalling and
transportation at the hepatocellular level. Although the
clinical association of cholestasis and inflammation are
established, recent studies demonstrated that alterations
of hepatic transport and metabolism occur early after
ICU admission [69, 70].
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In case of malabsorption, the reabsorption of bile
acids is reduced and the negative feedback for hepatic
bile acid synthesis is inhibited [70]. This mechanism
gives a rationale to study bile acid signalling mole-
cules as possible markers of malabsorption and the
effects of overproduction of bile acids due to malab-
sorption (gut-liver axis) on organ dysfunction and
outcome.
Other pathophysiological mechanisms in GI dysfunction
Pathophysiological mechanisms related to GI dysfunc-
tion with potentially impaired outcome in ICU pa-
tients are bowel oedema and distension. Gut oedema
occurs in the setting of inflammation and capillary
leak, fluid resuscitation and increased venous pres-
sure, whereas GI dysmotility may cause bowel disten-
sion. Both of them may contribute to (further
aggravation of) GI dysfunction.
Gut oedema Scarce existing evidence suggests that gut
oedema per se may lead to endotoxaemia, impair intes-
tinal motility and healing of bowel anastomoses, being
therefore an important contributor to the outcome.
A study in rodents reported similar activation of sig-
nalling pathways in response to intestinal oedema as to
mechanical longitudinal bowel distension [71]. Such
oedema-induced cell stretch and resulting altered cyto-
skeleton alterations may explain bowel dysmotility, im-
paired healing of anastomoses and also endotoxaemia-
mediated systemic effects. Bowel oedema can lead to
endotoxaemia [72], whereas the effect of oedema on
bowel motility may be comparable to the effect of peri-
tonitis [73]. In patients with increased mesenteric venous
pressure (caused by right heart failure, mesenteric hyper-
volaemia or increased intra-abdominal pressure), in-
creased drainage via lymphatics is necessary. With the
major increase in such filtration from the capillaries to
lymphatics, proteins will be washed out, leading to in-
creased interstitial oncotic pressure and the intestinal
interstitial space may become a space with high compli-
ance. The lymphatic flow will then be impaired, further
aggravating gut oedema [47].
Bowel distension Bowel distension relates to expansion
through increased intra- luminal pressure, manifesting
in clinical signs such as bloating or pain [74]. Whilst dis-
tension can lead to bowel perforation it can also increase
bacterial translocation and stimulate MODS [75].
Key remaining areas of uncertainty (what we do
not know)
Based on a review of the available literature, we identi-
fied several areas of uncertainty in GI dysfunction
(Table 2). In addition, specific topics with unclear
definitions were identified and prioritized for the con-
sensus process. We highlight the following topics:
1. Feeding intolerance: The large variety of definitions
is confusing the interpretation of different studies.
Consensus definition is needed to identify the
clinical importance of feeding intolerance and refine
management strategies.
2. Core set of daily monitoring of GI function:
Different definitions of different GI symptoms are
currently used in studies. Unification of reporting
should allow better comparisons of studies
regarding the prevalence and clinical relevance of
GI symptoms.
3. Core set of outcomes (core outcome set (COS)) in
studies addressing GI (dys)function: Unification of
reported outcomes would facilitate conduction of
meta-analyses.
4. Protocol of abdominal ultrasound to assess GI
function (collaboration with radiologists and
gastroenterologists): US could possibly supplement
the clinical assessment of GI dysfunction, but only
if applied in protocolized way.
5. Descriptive definition of non-occlusive mesenteric
ischaemia (collaboration with radiologists, gastroen-
terologists and surgeons): Consensus definition of
NOMI is needed to study epidemiology, risks, man-
agement and avoidance of this severe syndrome
which may sometimes be related to therapy pro-
vided to critically ill patients.
6. Reference methods to be used to measure gastric
emptying, absorption of nutrients and barrier
dysfunction in studies in critically ill patients
It should be recognized that in the light of the current
poor evidence, these consensus definitions will likely
need to be adapted in the future if new evidence
emerges. At the same time, they are crucial to produce
and systematize this new evidence.
Research agenda (what we need to know)
The panel formulated 32 study proposals (Add-
itional file 3, Table S4) that underwent voting. The
following studies (Table 3) were selected via voting
to have the priority using the methodology outlined
in Additional file 1:
Studies on prevention and management of diarrhoea
(ranks 1 and 3, respectively) as well as upper and
lower GI feeding intolerance (ranks 4 and 5) were
ranked high, stressing the perceived importance of
these very practical problems at the bedside and the
feasibility to study these issues. Future research on
diarrhoea and feeding intolerance is definitely not
limited to the proposed study ideas, offering a much
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Table 2 Remaining areas of uncertainty in gastrointestinal dysfunction of critically ill patients (what we do not know) We describe
these areas as high-level open-ended questions, to stimulate further research formulating specific questions. We highlight in bold
the subjects that were chosen by the panel for needing consensus process and prioritized as the next tasks for the Working Group
on GI function of the Section of MEN of ESICM
Subtopic Remaining areas of uncertainties
Monitoring of GI dysfunction
i. Clinical assessment How are GI symptoms* associated with GI function?
How to monitor GI function daily at bedside = what is the core set of
daily monitoring of GI function?
Which symptoms and when should trigger more complex diagnostics?
Whether a combination of clinical assessment with specific diagnostics/monitoring
methods could allow developing a reliable scoring system for GI dysfunction in critically ill?
How to define feeding intolerance?
What is the reference method to be used to measure gastric emptying in studies in
critically ill patients?
Can measurement of gastric residual volumes identify delayed gastric emptying?
Can monitoring of gastric residual volumes help in avoiding complications in patients with
feeding intolerance?
ii. Imaging What is the best abdominal ultrasound protocol for GI dysfunction? Needs collaboration
with radiologists and gastroenterologists.
Whether US image quality (which may be affected by air in the GI tract) can be further improved?
What imaging technique is associated with high inter-operator and over time reproducibility?
How to quantify bowel oedema?
iii. Laboratory (including biomarkers) Which biomarker(s) could be used as a marker of GI dysfunction?
Which biomarker(s) could be used in decision-making regarding enteral nutrition?
Which biomarkers could be used in decision-making regarding non-occlusive mesenteric
ischaemia?
iv. Absorption of nutrients What is the reference method to be used to measure absorption of nutrients in
studies in critically ill patients?
What are the possible novel methods to measure absorption of nutrients at bedside?
v. Barrier function What is the reference method to be used to measure barrier dysfunction in studies
in critically ill patients?
How to differentiate between pathological and physiological GI mucosal permeability?
What are the possible novel methods to measure/detect the presence of barrier dysfunction
in studies in critically ill patients?
What are the possible novel methods to estimate barrier dysfunction at bedside?
What are the possible biomarkers that can rapidly detect barrier dysfunction caused by
mesenteric ischaemia?
(How) does the microbiome influence the gut-derived immunity?
vi. Others Which GI symptoms could identify the cohort of patients who would benefit from
monitoring of intra-abdominal pressure?
What are the other possible novel strategies to monitor/assist in monitoring of GI function?
GI dysfunction: reporting and outcome
What is the natural course of GI dysfunction in survivors of critical illness?
Which are the differences between primary and secondary GI injury?
What is the core set of daily monitoring of GI function?
What are the ‘core outcomes’ for GI dysfunction in critically ill patients?
How to define non-occlusive mesenteric ischaemia (collaboration with radiologists,
gastroenterologists and surgeons)?
Management of GI dysfunction
vii. Prokinetics Which are the indications to use prokinetics?
Which novel prokinetic agents with less side effects could be used in clinical practice?
viii. Laxatives Which are the indications for laxative agents?
Which laxatives, when and in which dosage should be applied?
ix. Post-pyloric feeding Which are the indications to use post-pyloric feeding?
How does post-pyloric feeding compare to gastric feeding with prokinetic drugs on
patient-centred outcomes?
Are there differences between duodenal and jejunal feeding?
x. Others Which other management options could be used to prevent and/or improve GI dysfunction?
Could specific fluid resuscitation strategy reduce the prevalence and severity of GI dysfunction?
Could achievement of high-normal levels of electrolytes (potassium and magnesium) improve
GI motility?
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broader field. Studies on opioid antagonists (rank 2)
and indications for post-pyloric feeding (rank 7) also
refer to the management of feeding intolerance,
whereas testing of AGI grading (rank 9) as a clinical
bedside tool includes monitoring of feeding intoler-
ance. The role of intra-abdominal hypertension in de-
velopment of NOMI (rank 6), in development and in
monitoring of GI dysfunction (rank 8) and the effect of
proton pump inhibitors on microbiome of critically ill
(rank 10) were prioritized.
We want to emphasize the importance of all the
study proposals included in Table S4. The above-
presented ranking of the study projects also consid-
ered the feasibility of the projects. Feasibility of sev-
eral proposals could not be evaluated as ‘high’ due to
concerns about definitions, a priori necessary develop-
ment in methodology or very high costs, even though
the answers to raised research questions would be
most warranted. At the same time, feasible studies
gained higher ranking, explaining the prominent pos-
ition of rather straight-forward and practical studies
in the final list. However, e.g., studies on diarrhoea
also need to be seen in the context of later more so-
phisticated studies addressing feeding intolerance and
Table 2 Remaining areas of uncertainty in gastrointestinal dysfunction of critically ill patients (what we do not know) We describe
these areas as high-level open-ended questions, to stimulate further research formulating specific questions. We highlight in bold
the subjects that were chosen by the panel for needing consensus process and prioritized as the next tasks for the Working Group
on GI function of the Section of MEN of ESICM (Continued)
Subtopic Remaining areas of uncertainties
Could early mobilization improve GI function in ICU patients?
Which sedation strategy associated with less GI dysfunction?
xi. GI function and nutrition What is the optimal timing and duration for both trophic EN to ‘feed the mucosa
and microbiome’ and ‘full feeding’ to match estimated energy expenditure?
Does early EN benefits or harms GI function (e.g. absorptive capacity and barrier
function of the gut) when compared to fasting or PN?
Should intolerance of EN be accepted as a protective adaptive response to critical
illness or treated to increase nutrient delivery?
How and when should EN be initiated and/or increased to best maintain and/or
improve GI function?
Pathophysiological mechanisms in GI dysfunction relevant to the outcome
xii. The role of the gut in multiple organ
failure
What is the best definition and estimates of the prevalence of NOMI?
How to achieve earlier identification of NOMI (e.g. with additional biomarkers or other
tests of gut (hypo)perfusion)?
What are the feeding strategies to reduce the rate of NOMI (e.g. early fasting vs early
trophic EN)?
What interventions are effective in conservative management of NOMI?
When and how does GI injury cause multiple organ failure and vice versa?
xiii. Microbiome What mechanisms underlie changes in microbiota density, genus abundance, community
structure and function during critical illness?
Which role do microbiota-modulated metabolite function and inter-organ cross-talk play
in critically ill patients?
What are the causes and consequences of dysbiosis on gastrointestinal injury and organ
dysfunction?
Are there valid biomarkers for microbiome-related GI-dysfunction?
Can personalized microbiome type- and function-directed interventions improve organ
dysfunction and ICU-related outcomes?
What are the best sampling methods for the specimen (e.g. stool vs rectal swabs)?
xiv. Bacterial translocation /mucosal integrity Which are the mechanistic approaches to protect mucosal integrity?
Whether and how can/should the immune response on the loss of mucosal integrity be
modulated?
xv. GI hormones Which GI hormones are inadequately secreted in critical illness?
Quantify response to ‘normal’ endogenous or physiological concentrations?
What is the effect of restoring secretion of hormones/levels of hormones to ‘normal’
endogenous or physiological concentrations?
xvi. Bile acid signalling Could plasma concentrations of bile acid signalling molecules be used as a marker of
malabsorption?
xvii.
Others How does development of bowel oedema impact GI motility and vice versa?
What are the differences between the direct GI injury resulting in oedema vs GI injury
due to generalized oedema?
*GI symptoms include vomiting/regurgitation, abdominal distension, GI bleeding, diarrhoea and lower GI paralysis [3]. Expanded (if performed/possible to assess):
nausea, abdominal pain, absence of bowel sounds, large GRV (> 500 mL/6 h), bowel dilatation (radiological) and bowel wall thickening/bowel
oedema (radiological)
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malabsorption. The lack of uniformity/consensus in
definitions regarding GI function was recognized to
be a major limiting impact on future research. There-
fore, initiation of consensus processes on topics listed
in the previous section was formulated as the next
task of the WG.
Discussion of strengths and limitations
The main strength of this scoping review is the unified ef-
fort of a large group of experts to systematize available in-
formation and establish a framework to improve research
in this field. The main issues hindering any research on GI
dysfunction comprise the absence of uniform definitions
and the lack of gold-standard methods for measuring/
monitoring GI function.
Limitations of this work are that searches were limited
to the English language, the interpretation of current
evidence represents a consensus summary, the list of
study proposals is not exhaustive and both proposals
and current evidence may be influenced by individual
academic or industry bias despite the consensus ap-
proach. In addition, voting methodology emphasized
feasibility, which may rapidly change with advancement
in research methodology. Finally, all voting members
were clinician/researcher, and patients may have priori-
tized differently.
Conclusions
Despite the high morbidity, causes and consequences of
gastrointestinal dysfunction in critically ill patients are
insufficiently understood. To improve the consistency of
future studies, we propose the areas for consensus
process and outline future study projects. Studies on the
monitoring, prevention and management of diarrhoea
and feeding intolerance received the highest ranking on
the research agenda.
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